Drug intelligence / Profile preview

CX-188

Development stage: Discontinued
Lead developer: CytomX
Modality: Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CX-188 is a probody therapeutic composed of a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death protein 1 (PD-1). It was developed to inhibit PD-1, thereby enhancing immune responses against tumors. CX-188 was initially developed by CytomX Therapeutics for the treatment of solid tumors and other neoplasms. The drug reached Phase 1 clinical trials in adults with recurrent or metastatic solid tumors that had progressed on standard therapy, but its development has since been discontinued.

Other names: PD-1-directed probody CX-188PD1-directed probody CX-188PD 1-directed probody CX-188

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on CX-188.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX-188.

Explore the full profile